{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T02:01:00Z","timestamp":1712109660446},"reference-count":33,"publisher":"American Society of Consultant Pharmacists","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2010,9,1]]},"DOI":"10.4140\/tcp.n.2010.555","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:17:45Z","timestamp":1294885065000},"page":"555-569","source":"Crossref","is-referenced-by-count":1,"title":["Dronedarone: An Alternative to Amiodarone?"],"prefix":"10.4140","volume":"25","author":[{"given":"Peter J.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maisha Kelly","family":"Freeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances V.","family":"Cohenour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2010,9,27]]},"reference":[{"key":"1","unstructured":"Canham RM. Atrial fibrillation. In Cuculich PS, Kates AM, eds. The Washington Manual: Cardiology Subspecialty Consult. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:276-87."},{"key":"2","unstructured":"Sanoski CA, Schoen MD, Bauman JL. Arrhythmias. In Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. New York, NY: McGraw Hill Medical; 2008:289."},{"key":"3","unstructured":"Rudolf M, Lip G, Bakshi L et al. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London, UK: Royal College of Physicians; 2006:12-15, 55. Available at <a target=\"_blank\" href='http:\/\/www.nice.org.uk\/nicemedia\/pdf\/cg036fullguideline.pdf'>http:\/\/www.nice.org.uk\/nicemedia\/pdf\/cg036fullguideline.pdf<\/a>"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Fuster V, Ryd\u00e9n LE, Cannom DSet al. ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:155-354.","DOI":"10.1161\/CIRCULATIONAHA.106.177292"},{"key":"5","unstructured":"Micromedex Healthcare Series Web Site. Available at <a target=\"_blank\" href='http:\/\/www.thomsonhc.com'>http:\/\/www.thomsonhc.com<\/a>"},{"key":"6","unstructured":"FDA Web site. Available at <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDrugDet'>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDrugDet<\/a>"},{"key":"7","unstructured":"Multaq [package insert]. Bridgewater, NJ: sanofi-aventis; 2009. Available at <a target=\"_blank\" href='http:\/\/products.sanofi-aventis.us\/multaq\/multaq.html'>http:\/\/products.sanofi-aventis.us\/multaq\/multaq.html<\/a>"},{"key":"8","unstructured":"Clinical Pharmacology Web Site. Available at <a target=\"_blank\" href='http:\/\/clinicalpharmacology-ip.com.ezproxy.samford.edu\/'>http:\/\/clinicalpharmacology-ip.com.ezproxy.samford.edu\/<\/a>"},{"key":"9","unstructured":"Cordarone [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008. Available at <a target=\"_blank\" href='http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=8777'>http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=8777<\/a>"},{"key":"10","unstructured":"Amiodarone [package insert]. Pomona, NJ: Barr Laboratories, Inc.; 2008. Available at <a target=\"_blank\" href='http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=6615'>http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=6615<\/a>"},{"key":"11","unstructured":"American Hospital Formulary Service online. Available at <a target=\"_blank\" href='http:\/\/www.crlonline.com'>http:\/\/www.crlonline.com<\/a>"},{"key":"12","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/01.CIR.100.22.2276","article-title":"Electrophysiological effects of dronedarone (SR33589), a noniodionated benzofuran derivative, in the rabbit heart: comparison with amiodarone.","volume":"100","author":"W Sun","year":"1999","journal-title":"Circulation"},{"key":"13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1046\/j.1540-8167.2003.03064.x","article-title":"Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.","volume":"14","author":"N Lalevee","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"14","unstructured":"FDA advisory committee program. FDA resources page. Food and Drug Administration Web site. Available at <a target=\"_blank\" href='http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4417b1-02-sanofi_aventis.pdf'>http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4417b1-02-sanofi_aventis.pdf<\/a>"},{"key":"15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2125.2007.02998.x","article-title":"Effect of dronedarone on renal function in healthy subjects.","volume":"64","author":"Y Tschuppert","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"16","unstructured":"sanofi-aventis. US FDA Cardiovascular & Renal Drugs Advisory Committee: briefing material for dronedarone [online]. Available at <a target=\"_blank\" href='http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4417b1-01-FSA.pdf'>http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4417b1-01-FSA.pdf<\/a>"},{"key":"17","unstructured":"Renal and Cardiovascular Docket Briefing. <a target=\"_blank\" href='http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM176354.pdf'>http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM176354.pdf<\/a>"},{"key":"18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0195-668X(03)00321-X","article-title":"Dronedarone for prevention of atrial fibrillation: a dose-ranging study.","volume":"24","author":"P Touboul","year":"2003","journal-title":"Eur Heart J"},{"key":"19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.","volume":"357","author":"BN Singh","year":"2007","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure.","volume":"358","author":"L Kober","year":"2008","journal-title":"N Engl J Med"},{"key":"21","article-title":"Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study","volume":"156","author":"JM Davy","year":"2008","journal-title":"Am Heart J"},{"key":"22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation.","volume":"360","author":"SH Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1074248406290678","article-title":"Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions.","volume":"11","author":"N Wadhani","year":"2006","journal-title":"J Cardiovasc Pharamcol Ther"},{"key":"24","first-page":"209","article-title":"Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents, and acquired long QT syndrome.","volume":"15","author":"A Riera","year":"2008","journal-title":"Cardiol J"},{"key":"25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejphar.2007.02.052","article-title":"Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.","volume":"564","author":"MG Agelaki","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1476-5381.1995.tb16397.x","article-title":"Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in the rat heart.","volume":"116","author":"P Chatelain","year":"1995","journal-title":"Br J Pharmacol"},{"key":"27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/en.2002-220604","article-title":"Dronedarone acts as a selective inhibitor of 3-5 Triiodothyronine binding to thyroid hormone receptor \u2013 1: in vitro and in vivo evidence.","volume":"144","author":"HC Van Beeren","year":"2003","journal-title":"Endocrinology"},{"key":"28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1472-8206.2003.00216.x","article-title":"Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers health subjects.","volume":"18","author":"T Damy","year":"2004","journal-title":"Fun Clin Pharm"},{"key":"29","unstructured":"European Medicines Agency. Assessment Report for Multaq. Available at <a target=\"_blank\" href='http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/multaq\/h-1043en6.pdf'>http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/multaq\/h-1043en6.pdf<\/a>"},{"key":"30","unstructured":"Mitchell JF. Oral dosage forms that should not be crushed. Available at <a target=\"_blank\" href='http:\/\/www.ismp.org\/Tools\/DoNotCrush.pdf'>http:\/\/www.ismp.org\/Tools\/DoNotCrush.pdf<\/a>"},{"key":"31","unstructured":"Lexi-Comp Online Web site. Available at <a target=\"_blank\" href='http:\/\/www.crlonline.com.ezproxy.samford.edu\/'>http:\/\/www.crlonline.com.ezproxy.samford.edu\/<\/a>"},{"key":"32","unstructured":"Facts and Comparison Web site. Available at <a target=\"_blank\" href='http:\/\/online.factsandcomparisons.com.ezproxy.samford.edu\/'>http:\/\/online.factsandcomparisons.com.ezproxy.samford.edu\/<\/a>"},{"key":"33","unstructured":"Redbook March 2010 Update. Montvale, NJ: Thomson Healthcare; 2010:14, 48."}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:21:13Z","timestamp":1712103673000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2010\/00000025\/00000009\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9,1]]}},"alternative-id":["733031P625G13070"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2010.555","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}